Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Interest Expenses (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Interest Expenses for 6 consecutive years, with $7.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 7.58% year-over-year to $7.1 million, compared with a TTM value of $29.1 million through Dec 2025, down 4.7%, and an annual FY2025 reading of $29.1 million, down 4.64% over the prior year.
  • Interest Expenses was $7.1 million for Q4 2025 at Xeris Biopharma Holdings, down from $7.3 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $8.0 million in Q2 2024 and bottomed at $1.8 million in Q1 2021.
  • Average Interest Expenses over 5 years is $5.4 million, with a median of $6.7 million recorded in 2023.
  • The sharpest move saw Interest Expenses fell 22.98% in 2021, then surged 122.48% in 2022.
  • Year by year, Interest Expenses stood at $1.8 million in 2021, then soared by 76.11% to $3.2 million in 2022, then surged by 121.59% to $7.0 million in 2023, then increased by 9.86% to $7.7 million in 2024, then decreased by 7.58% to $7.1 million in 2025.
  • Business Quant data shows Interest Expenses for XERS at $7.1 million in Q4 2025, $7.3 million in Q3 2025, and $7.4 million in Q2 2025.